Concepedia

Ana M. Molina

AM

Statistics

Publications

67

Citations

4.9K

H-Index

35

Active since

2006

Affiliations

Cornell University(Current)

Weill Cornell Medicine

Memorial Sloan Kettering Cancer Center

NewYork–Presbyterian Hospital

New York Hospital Queens

Ana M. Molina is an author at Cornell University specializing in medicine, oncology, and renal cell carcinoma.

Publications per year

2006–2025

67

Publications

67

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology · 2015 · 943 citations · Full text

Medicine, Oncology, Pharmacology +14

Clinical features of neuroendocrine prostate cancer

Vincenza Conteduca, Clara Oromendia, Kenneth Eng et al. · European Journal of Cancer · 2019 · 363 citations

Medicine, Oncology, Urology +14

Clonal evolution of chemotherapy-resistant urothelial carcinoma

Bishoy M. Faltas, Davide Prandi, Scott T. Tagawa et al. · Nature Genetics · 2016 · 301 citations · Full text

Medicine, Cancer Biology, Oncology +14

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

Brian D. Robinson, Panagiotis J. Vlachostergios, Bhavneet Bhinder et al. · Nature Communications · 2019 · 212 citations · Full text

Medicine, Cancer Biology, Urology +17

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

1–5 of 67